NewAmsterdam Pharma (NAMS) Return on Sales (2023 - 2025)
Historic Return on Sales for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 206.91%.
- NewAmsterdam Pharma's Return on Sales fell 2063400.0% to 206.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.27%, marking a year-over-year decrease of 3500.0%. This contributed to the annual value of 5.3% for FY2024, which is 72600.0% up from last year.
- As of Q3 2025, NewAmsterdam Pharma's Return on Sales stood at 206.91%, which was down 2063400.0% from 0.91% recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Return on Sales ranged from a high of 0.57% in Q3 2024 and a low of 206.91% during Q3 2025
- Over the past 3 years, NewAmsterdam Pharma's median Return on Sales value was 14.65% (recorded in 2023), while the average stood at 39.54%.
- Per our database at Business Quant, NewAmsterdam Pharma's Return on Sales surged by 543900bps in 2024 and then plummeted by -2063400bps in 2025.
- NewAmsterdam Pharma's Return on Sales (Quarter) stood at 61.6% in 2023, then surged by 88bps to 7.22% in 2024, then tumbled by -2767bps to 206.91% in 2025.
- Its last three reported values are 206.91% in Q3 2025, 0.91% for Q2 2025, and 13.27% during Q1 2025.